As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation–Positive Langerhans Cell Histiocytosis
Presentation # 3618 – Poster
December 13, 2021 | 06:00 PM EST